The flags have been furled, poster boards packed away, and ASCO planners are already getting ready for another year.
The annual meeting of the American Society of Clinical Oncology (ASCO) provided an important snapshot of the state of clinical research in oncology, bringing together some 6,000 presentations and around 32,000 oncology professionals from across the globe.
Now, before attention turns to the next major event, we recap some of the key highlights and learnings from the industry’s preeminent cancer conference.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze